Avadel Prescribed drugs falls as This autumn income misses estimates; shares sink 20%

DUBLIN – Avadel Prescribed drugs plc (NASDAQ:AVDL) reported preliminary fourth quarter income under analyst expectations, sending shares tumbling 20% in after-hours buying and selling.

The biopharmaceutical firm, targeted on sleep problem remedies, estimated This autumn web product income of roughly $50.0 million, falling in need of the $52.7 million consensus estimate.

Regardless of lacking expectations, Avadel’s This autumn income represents a greater than 150% enhance in comparison with $19.5 million in the identical quarter final yr. The corporate famous that fourth quarter income was impacted by roughly $6.0 million attributable to an estimated 1.5 fewer weeks of stock within the channel at December 31, 2024, in comparison with September 30, 2024.

For the total yr 2024, Avadel generated web product income of roughly $169.0 million, up considerably from $28.0 million in 2023. The corporate ended the quarter with a optimistic money movement, reporting roughly $73.0 million in money, money equivalents and marketable securities as of December 31, 2024.

Greg Divis, Chief Government Officer of Avadel Prescribed drugs, commented on the outcomes: “2024 was a pivotal yr for Avadel, marked by constant affected person adoption of LUMRYZ and overwhelmingly optimistic suggestions from each sufferers and suppliers concerning the transformative advantages of once-nightly dosing.”

Trying forward, Avadel offered steering for LUMRYZ web product income of $240 – $260 million in 2025, representing 50% YoY development on the midpoint. The corporate additionally reported 2,500 sufferers on LUMRYZ as of December 31, 2024, together with 600 sufferers that initiated remedy within the fourth quarter.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.